CA3233234A1 - Drug for treating fatty liver and nonalcoholic steatohepatitis - Google Patents

Drug for treating fatty liver and nonalcoholic steatohepatitis Download PDF

Info

Publication number
CA3233234A1
CA3233234A1 CA3233234A CA3233234A CA3233234A1 CA 3233234 A1 CA3233234 A1 CA 3233234A1 CA 3233234 A CA3233234 A CA 3233234A CA 3233234 A CA3233234 A CA 3233234A CA 3233234 A1 CA3233234 A1 CA 3233234A1
Authority
CA
Canada
Prior art keywords
amino acid
fatty liver
peptide
acid sequence
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233234A
Other languages
English (en)
French (fr)
Inventor
Katsuto Tamai
Takashi SHIMBO
Shuji Terai
Atsunori TSUCHIYA
Takehiko Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niigata University NUC
StemRIM Inc
University of Osaka NUC
Original Assignee
Niigata University NUC
Osaka University NUC
StemRIM Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Niigata University NUC, Osaka University NUC, StemRIM Inc filed Critical Niigata University NUC
Publication of CA3233234A1 publication Critical patent/CA3233234A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3233234A 2021-09-30 2021-09-30 Drug for treating fatty liver and nonalcoholic steatohepatitis Pending CA3233234A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2021/036238 WO2023053384A1 (ja) 2021-09-30 2021-09-30 脂肪肝および非アルコール性脂肪肝炎の治療薬

Publications (1)

Publication Number Publication Date
CA3233234A1 true CA3233234A1 (en) 2023-04-06

Family

ID=85781770

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233234A Pending CA3233234A1 (en) 2021-09-30 2021-09-30 Drug for treating fatty liver and nonalcoholic steatohepatitis

Country Status (9)

Country Link
US (1) US20240299496A1 (https=)
EP (1) EP4410302A4 (https=)
JP (1) JP7798300B2 (https=)
KR (1) KR20240070640A (https=)
CN (1) CN118317780A (https=)
AU (1) AU2021466375A1 (https=)
CA (1) CA3233234A1 (https=)
MX (1) MX2024003974A (https=)
WO (2) WO2023053384A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3358011T (pt) 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
US20200038486A1 (en) 2017-04-07 2020-02-06 StemRIM Inc. Therapeutic medicine for fibrous disease
EP3728593A1 (en) * 2017-12-18 2020-10-28 Alnylam Pharmaceuticals, Inc. High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms

Also Published As

Publication number Publication date
US20240299496A1 (en) 2024-09-12
EP4410302A1 (en) 2024-08-07
EP4410302A4 (en) 2025-07-23
AU2021466375A1 (en) 2024-04-11
KR20240070640A (ko) 2024-05-21
WO2023054666A1 (ja) 2023-04-06
CN118317780A (zh) 2024-07-09
JPWO2023053384A1 (https=) 2023-04-06
WO2023053384A1 (ja) 2023-04-06
MX2024003974A (es) 2024-07-09
JP7798300B2 (ja) 2026-01-14

Similar Documents

Publication Publication Date Title
JP7670749B2 (ja) Ｎａｓｈおよびその他障害の処置用の改善されたペプチド薬剤
US11298403B2 (en) Therapeutic agent for inflammatory bowel disease
ES2523463T3 (es) Composiciones para inhibir la angiogénesis
EP3603660B1 (en) Long-acting mutant human fibroblast growth factor 21 for treating non-alcoholic steatohepatitis
JP2017526713A (ja) 線維症を処置するためのセニクリビロック併用療法
US20200038486A1 (en) Therapeutic medicine for fibrous disease
KR20130066626A (ko) 항ｃｄ3 면역 분자 요법을 사용하여 간염을 치료하는 방법 및 이를 위한 조성물
CN104602699B (zh) 含c‑肽的用于预防或治疗糖尿病性血管生成损伤的组合物
EP3344279B1 (en) Methods for treating heart failure using glucagon receptor antagonistic antibodies
US20240299496A1 (en) Drug for treating fatty liver and nonalcoholic steatohepatitis
HK40107111A (en) Drug for treating fatty liver and non-alcoholic steatohepatitis
CN114432317A (zh) 吡咯并嘧啶类化合物的用途
KR20230104903A (ko) Eomes 양성 CD4 양성 T 세포의 증가에 기인하는 진행형 질환 치료제
CN119499255A (zh) 一种化合物在治疗肝病中的应用
CN118634316A (zh) 一种预防和治疗胆汁淤积症的司美格鲁肽联合用药组合物
KR102445482B1 (ko) 오가노이드 및 항염증제를 포함하는 염증성 장질환의 예방 또는 치료용 약학 조성물
TW202317110A (zh) 用於治療肝臟疾病的聯合治療
Yanagi et al. mRNA vaccination mitigates pathological retinochoroidal neovascularization in animal models
US20230201311A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis (nash)
KR20240083161A (ko) 리포칼린 2 억제제를 포함하는 간섬유화 예방 또는 치료용 약학적 조성물
US20190192458A1 (en) Therapeutic/prophylactic agent for graft-versus-host disease, fibrocyte invasion inhibitor, and inhibitor against tear reduction and reduction in goblet cells
CN120678789A (zh) 木犀草素-7-二葡萄糖醛酸苷在制备抗肝脏纤维化相关疾病的药物中的应用
CN120131939A (zh) 地舒单抗在制备抗股骨头坏死药物中的应用
CN121693519A (zh) Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
WO2006006751A1 (en) A composition comprising purified extract of wild ginseng having neuronal cell protecting activity

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250708

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250708

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250905

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250905

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250905